How investors reacted to Valeant's $2.1B sell off: 4 key insights

After announcing plans to sell off four company assets, investors rallied behind Lovell, Canada-based Valeant Pharmaceuticals.

The company is attempting to lower its $30 billion in accrued debts.

Here is what you need to know.

1. Valeant shares closed Jan. 9, 2017 at $15.35 and opened the following day at $17.12 following the acquisition news.

2. The company ended its day at $16.42. As of 11 a.m. EST, Jan. 11, 2017, Valeant was trading at $16.26.

3. Valeant's 52-week range is between $13 and $101.40.

4. The company has a market cap of $5.93 billion.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast